Charles River Laboratories (CRL)
Debt-to-equity ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 3,461,500 | 3,782,270 | 3,722,730 | 3,640,440 | 3,596,880 | 3,305,990 | 3,251,700 | 3,108,600 | 2,976,290 | 2,626,850 | 2,647,710 | 2,610,180 | 2,534,820 | 2,426,570 | 2,318,440 | 2,183,930 | 2,114,600 | 1,896,940 | 1,752,640 | 1,651,980 |
Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $3,461,500K
= 0.00
The debt-to-equity ratio of Charles River Laboratories has consistently remained at 0.00 across all the reported financial periods from March 31, 2020, to December 31, 2024. This implies that the company has not utilized any debt to finance its operations or investments during this period. A debt-to-equity ratio of 0.00 indicates that the company has relied solely on equity financing, which can be considered a positive indicator of financial stability and lower financial risk. It suggests that Charles River Laboratories has a strong financial position and has not accumulated any significant debt obligations relative to its equity. A consistent zero debt-to-equity ratio may reflect a conservative financial strategy or a lack of opportunities or needs to leverage debt in its capital structure.
Peer comparison
Dec 31, 2024